U.S. markets close in 2 hours 39 minutes
  • S&P 500

    3,769.17
    -14.11 (-0.37%)
     
  • Dow 30

    30,118.36
    -155.51 (-0.51%)
     
  • Nasdaq

    11,142.99
    -5.65 (-0.05%)
     
  • Russell 2000

    1,758.97
    -3.72 (-0.21%)
     
  • Crude Oil

    88.27
    +0.51 (+0.58%)
     
  • Gold

    1,719.70
    -1.10 (-0.06%)
     
  • Silver

    20.59
    +0.05 (+0.25%)
     
  • EUR/USD

    0.9813
    -0.0072 (-0.73%)
     
  • 10-Yr Bond

    3.8120
    +0.0530 (+1.41%)
     
  • GBP/USD

    1.1166
    -0.0156 (-1.38%)
     
  • USD/JPY

    144.9080
    +0.2980 (+0.21%)
     
  • BTC-USD

    20,100.54
    -142.00 (-0.70%)
     
  • CMC Crypto 200

    457.42
    -5.70 (-1.23%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Amneal to Participate at the 2022 Jefferies Healthcare Conference

·1 min read

BRIDGEWATER, N.J., May 24, 2022--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2022 Jefferies Healthcare Conference held on June 8, 2022 in New York City. Mr. Patel will also be hosting a presentation which will begin at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005512/en/

Contacts

Tony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com